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Abstract
We tested whether amorphous SiO2-NPs and formyl-
peptide receptor (FPRs) agonists synergistically activate
human monocytes and neutrophil polymorphonuclear
granulocytes (PMNs). Peptide ligands specifically binding
to FPR1 (f-MLP) and to FPR2 (MMK-1, WKYMVM and
WKYMVm) human isoforms did not modify the associa‐
tion of SiO2-NPs to both cell types or their cytotoxic effects.
Similarly, the extent of CD80, CD86, CD83, ICAM-1 and
MHCII expression in monocytes treated with SiO2-NPs was
not significantly altered by any FPRs agonist. However,
FPR1 stimulation with f-MLP strongly increased the
secretion of IL-1β, IL-6 and IL-8 by human monocytes, and
of IL-8 by PMNs in the presence of SiO2-NPs, due to the
synergic stimulation of gene transcription. FPR2 agonists
also up-modulated the production of IL-1β induced by
monocytes treated with SiO2-NPs. In turn, SiO2-NPs
increased the chemotaxis of PMNs toward FPR1-specific
ligands, but not toward FPR2-specific ones. Conversely, the
chemotaxis of monocytes toward FPR2-specific peptides
was inhibited by SiO2-NPs. NADPH-oxidase activation
triggered by FPR1- and FPR2-specific ligands in both cell
types was not altered by SiO2-NPs. Microbial and tissue
danger signals sensed by FPRs selectively amplified the
functional responses of monocytes and PMNS to SiO2-NPs,
and should be carefully considered in the assessment of the
risk associated with nanoparticle exposure.
Keywords Silica Nanoparticles, Monocytes, PMNs, Formyl
Peptide Receptors, Immunomodulation
1. Introduction
Cytotoxicity and inflammation are dangerous adverse
events that may be associated with nanomedical applica‐
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tions [1]. Indeed, many nanosystems induce cell death and
an increased synthesis of cytokines and chemokines, both
in vitro and in vivo [2-4]. Amorphous silica is considered
more biocompatible than highly toxic crystalline silica and
has therefore been proposed as a nanomaterial [5]. How‐
ever, amorphous nanosilica has cytocidal and pro-inflam‐
matory properties as well, including the ability to induce
the secretion of powerful cytokines by myeloid cells such
as IL-1β and TNFα. In vitro studies indicate that toxicity
and cytokines synthesis are triggered by SiO2-NPs above a
threshold concentration. In addition, inflammatory
immune cells like monocytes and macrophages are about
10 times more sensitive to the toxic action of SiO2-NPs than
non-phagocytic leukocytes and epithelial cell lines [6]. This
higher sensitivity of monocytes/macrophages to amor‐
phous SiO2-NPs is likely due to their higher capturing
efficacy, leading to NPs’ intracellular accumulation up to a
critical level and determining cell death [6]. Available
evidence indicates amorphous silica particles induce
maturation and secretion of IL1β in monocytes and
macrophages by activating caspase-1 [6-8]. Recent data
suggest that the activation of caspase-1 by SiO2-NPs also
mediates pyroptotic, pro-inflammatory cell death in
monocytes, a phenomenon that may further exacerbate
tissue inflammation [6].
However, it is possible that the adverse reactions to SiO2-
NPs and their intensities are only partially estimated, based
on these in vitro evidence. Other factors generated in vivo
may synergize with the action of NPs. In particular, co-
stimulation with microbial agonists (PAMPs) may contrib‐
ute to the activity of nanomaterials. For example, LPS, the
major outer membrane component of Gram- bacteria, has
been long known to upregulate the ability of nano-micro
particulates to induce IL1-β secretion in macrophages and
monocytes  [6-9].  While  macrophage endocytosed nano-
micro  particulates  eventually  activate  caspase-1,  LPS
stimulates  the  NFK-b  dependent  transcription  of  pro-
IL1β. Some evidence also suggests that LPS may improve
the  cytotoxic  effect  of  nanoparticles  [9].  In  addition,  f-
MLP, a prototype of prokaryotic-derived formylated leader
sequences, synergizes the induction of various cytokines by
both naked and PEGylated ORMOSIL-NPs, liposomes and
PLGA-NPs [10]. N-formylated peptides bind to a group of
seven-transmembrane-domain Gi protein-coupled recep‐
tors (GPCR), called FPRs (formyl peptide receptors), which
are expressed by myeloid cells. Nanomolar or sub-nanomo‐
lar  concentrations of  FPRs-specific  ligands are  a  potent
alarm signal for inflammatory and immune cells, indicat‐
ing the presence of an infection. The activation of FPRs
determine a multiple response, aimed at recruiting more
defensive inflammatory cells in the infected tissue and the
elimination  of  invading  microbes.  These  FPR-mediated
effects  include  intracellular  calcium  mobilization,  the
activation  of  antimicrobial  mechanisms  like  NADPH
oxidase and the degranulation and stimulation of chemotax‐
is. In humans, three FPR homologues are known: FPR1,
FPR2 and FPR3. FPR1 binds with high affinity (Kd in the nM
range) to N-fMLP and other N-formylated peptides from L.
monocytogenes [11-13]. FPR2 binds with low affinity to f-
MLP (Kd in the µM range), but with nanomolar affinities to
several microbial derived molecules (the peptide Hp(2-20)
from H. Pylori [14], formylated peptides from L. monocyto‐
genes  and staphylococcal phenol-soluble modulins [15]).
Interestingly, a set of various host-derived peptides and
molecules also bind to FPR2: annexin-derived Ac1-25, the
antimicrobial peptide cathelicidin LL37, a fragment of the
urokinase receptor, serum amyloid A, amyloid b peptide
(Aβ42), the prion protein fragment PrP(106-126) [14] and the
anti-inflammatory  lipid  mediator  lipoxin  A4  [16].  The
binding specificity of FPR3 is the least characterized of the
three human isoforms. It does not bind to N-fMLP, but
specifically  associates  with  the  acetylated  N-terminal
peptide in human haem-binding protein [17]. FPR1 and
FPR2 are both expressed in PMNs and monocytes, while
FPR3 is only present in monocytes and DCs [14].
The above summarized FPRs specificities suggest that
while FPR1 monitors bacterial infections, FPR2, due to its
promiscuous binding capability, is sensitive to both
bacterial presence and tissue alterations. However, such a
functional distinction between FPR1 and FPR2 is not clear-
cut, because, for example, formylated peptides from
mitochondrial proteins (like NADH dehydrogenase and
Cox subunits) bind to both FPR1 and FPR2 with similar
high affinities (Kd range 12-210 nM) [13]. Since mitochon‐
dria-derived formyl-peptides are released into the extrac‐
ellular space during necrosis, FPR1 likely also plays a
crucial role in the recruitment and activation of leukocytes
in pathologies characterized by sterile inflammation and
tissue damage [18]. A recent analysis showing that FPRs
can recognize common structural motives present in
hundreds of microbial and tissue peptides supports the
hypothesis that this versatile receptor family has a central
homeostatic role in mammals by monitoring their micro‐
bioma [19].
Some synthetic peptides identified in random peptide
libraries are valuable tools for studying the function of
different FPRs isoforms. The MMK-1 peptide, which has a
sequence of LESIFRSLLFRVM [20], is a FPR2 specific
agonist able to induce Ca2+ mobilization in FPR2-transfect‐
ed cells with an EC50 of around 2 nM [21]. Similar effects
on cytosolic calcium were observed in monocytes and
PMNs in the same nmolar range. MMK-1 also induces
chemotaxis with a maximum at about 1 µM in both
monocytes and PMNs and NADPH-oxidase dependent
ROS [22]. WKYMVM activates FPR2-transfected HL60 cells
with an EC50 of about 2 nM and FPR3-transfected ones
with an EC50 of around 80 nM, but does not stimulate
FPR1-expressing cells [23]. WKYVMVm binds to all FPR
isoforms with different affinities: at picomolar concentra‐
tions to FPR2 (Kd 75 pM) and in the nanomolar range to
FPR3 (Kd 3 nM) and to FPR1 (Kd 25 nM). Consequently,
WKYMVm is the most effective FPRs agonist able to induce
chemotaxis and NADPH-oxidase activation in PMNS and
monocytes at very small doses [24].
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In synthesis, FPRs may be considered unique PRR recep‐
tors, able to sense both PAMPs and DAMPs. For this reason,
in this study, we decided to examine the possibility that
nanoparticles act synergistically with FPRs’ activation.
Human PMNs and monocytes were incubated using the
nanosystem amorphous silica model, with NPs in the
absence or in the presence of the FPR specific peptides, as
summarized in Table 1.
FPR1 FPR2 (FPR1-L) FPR3 (FPR2-L)
PMNs + + -
Monocytes + + +
f-MLP 1-3 nM 1 µM No binding
MMK-1 No binding 2 nM 10 µM
WKYMVM No binding 2nM 80 nM
WKYMVm 25 nM 0.075 nM 3nM
Table 1. Expression of formyl peptide receptors on human PMNs and
monocytes and the affinity (Kd) of different FPR agonists for different FPR
isoforms [14]
SiO2-NPs doses and incubation times (generally 50 and 100
µg/ml for 24 hours) were calibrated based on our previous
study [6] and showed that both Ludox and Stöber silica NPs
(diameter 24 and 27nm, respectively) had intrinsic pro-
inflammatory and cytotoxic effects on monocytes in these
conditions.
Cytotoxicity, superoxide anion induction, overexpression
of CD markers involved in antigen presentation, cytokine
production and chemotaxis were analysed. Results indicate
a reciprocal interaction between FPR activation and SiO2-
NPs action on both PMNs and monocytes, eventually
leading to a stronger inflammogenic response from these
cells.
2. Material and Methods
2.1 Nanoparticles
LUDOX® TM40 colloidal silica nanoparticles (NPs) (40%
wt. suspension in H2O) were purchased from Sigma
Aldrich. Nanoparticles’ DLS measurements provided an
average diameter of 28 nm with a 0.205 PDI (in phosphate-
buffered saline [PBS], pH 7.4). The zeta-potential value
(same conditions as DLS analysis) was -13.7 mV and TEM
analysis yielded a 27 nm diameter in good agreement with
the DLS size. All NPs suspensions were endotoxin free
(<0.05 Endotoxin units/ml, as measured by a Limulus test).
Stöber nanoparticles were prepared as previously descri‐
bed [6]. DLS measurements provided an average diameter
of 30 nm with a 0.198 PDI (in phosphate-buffered saline
[PBS], pH 7.4); zeta-potential value (same conditions as
DLS analysis) was -18.8 mV and TEM analysis yielded a 24
nm diameter.
2.2 Purification of monocytes and PMN
Peripheral blood mononuclear cells (PBMC) were isolated
from the buffy coats of healthy donors by centrifugation
over a Ficoll-hypaque (Amersham Biosciences) step
gradient and a subsequent Percoll (Amersham Biosciences)
gradient, and suspended in RPMI-1640 (GIBCO BRL)
supplemented with antibiotic. Residual T and B cells were
removed from the monocyte fraction by plastic adherence
for 1 hour at 37°C. The purity of preparations (percentage
of CD14-positive cells) and cell viability (using the trypan
blue exclusion test) were both higher than 98%. For human
PMNs purification, after centrifugation of buffy coats
through a Ficoll-hypaque gradient, red blood cells con‐
tained in the bottom fraction were eliminated by dextran
sedimentation, followed by hypotonic lysis and washing
with PBS. The percentage of contaminating cells was <5%.
Unless otherwise specified, monocytes and PMNs were
kept at 37°C in a humidified atmosphere containing 5% (v/
v) CO2 in RPMI-1640 and supplemented with antibiotic and
10% FCS (Euroclone).
2.3 Measurement of IL-1β, IL-6 and IL-8 production by
monocytes and PMNs
2x106 Monocytes or PMNs were incubated with different
concentrations (50-100-200 µg/ml) of NPs and in presence
or absence of different bacterial stimuli (fMLP from Sigma
Aldrich, MMK1, WKYMVM and WKYMVm from Tocris
Bioscience) for 20h at 37°C. Culture supernatants were
collected and the amount of IL-1β, IL-6 and IL-8 protein was
quantified by ELISA assay, following the manufacturer’s
instructions.
2.4 Real-time PCR analysis
2x106 Monocytes were incubated for five hours at 37°C, as
previously described. Treated and untreated cells were
scraped and total RNAs were isolated using a TRIzol
solution (SIGMA), according to the manufacturer’s instruc‐
tions, and suspended in 12 µl of RNase-free water (Gibco).
RNA was quantified by spectrophotometric analysis
(NanoDrop® ND-1000 Spectrophotometer, CELBIO).
Equal amounts of RNA (300 ng) was retrotranscripted and
the concentration of cDNA for IL-1β, IL-6, IL-8 and TNF-
α were quantified by real time quantitative PCR using an
iQTM SYBR Green Supermix (Biorad) and an iQ5 2.0 Biorad
System, according to the manufacturer’s instructions
(Biorad). The following primers were used: for GAPDH, 5’-
AGCAACAGGGTGGTGGAC-3’ and 5’-
GTGTGGTGGGGGACTGAG-3’; for IL-1β, 5’-
CTGTCCTGCGTGTTGAAAGA-3’ and 5’-
TTGGGTAATTTTTGGGATCTACA-3’; for IL-6, 5’-
AACCTGAACCTTCCAAAGATGG-3’ and 5’-
TCTGGCTTGTTCCTCACTACT-3’; for IL-8, 5’-
TTGGCAGCCTTCCTGATT-3' and 5’-
AACTTCTCCACAACCCTCTG-3'; for TNF-α, 5’-
ATGAGCACTGAAAGCATGATC-3’ and 5’-
GAGGGGCTGATTAGAGAGAGGT-3’.
Each run was completed with a melting curve analysis to
confirm the specificity of amplification and lack of primers’
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dimers. CT (cycle threshold) values were determined by the
GeneAmp 5700 SDS software using fluorescence threshold,
manually set and exported into Excel for analysis. Follow‐
ing the amplification, data analysis was performed using
the second derivative method algorithm. For each sample,
the amount of messenger RNA (mRNA) of the cytokines
was expressed as the n-fold of the normalized amount of
mRNA in untreated cells (1 arbitrary unit = cytokine mRNA
concentration/GAPDH mRNA concentration [both in
fmoles/µl]).
2.5 Measurement of marker expression by flow cytometry
analysis
Monocytes (2x106) were incubated in the presence of
different bacterial stimuli for 20 hours with 50 µg/ml of NPs
in a RPMI-1640 medium, supplemented with 10% FCS at
37°C. Cells incubated with no nanoparticles were used as a
negative control. Cells were then washed with phosphate-
buffered saline pH 7.2, scraped, centrifuged, resuspended
in a FACS buffer (PBS containing 1% FCS and 0.1% NaN3)
and then further incubated with the proper dilution of
different anti-CD monoclonal antibodies (CD80, CD83,
CD86, ICAM-1 and MHC-II, Biolegend), and conjugated to
phycoerythrin (PE) for 30 minutes on ice. After a wash with
the FACS buffer, propidium iodide was added to exclude
dead cells and the cell fluorescence intensities of the gated
populations were measured with a FACS Canto flow
cytometer, and analysed using FACSDiva software (Becton
Dickinson).
2.6 NPs association to monocytes and PMNs
Monocytes and PMNs (2x106), seeded onto 24-well plates,
were incubated with different concentrations (up to 200 µg/
ml) of Stöber NPs for 24 hours in a RPMI-1640 medium,
supplemented with 10% FCS, at 37°C, in the presence or
absence of bacterial stimuli. Then cells were collected,
washed with PBS and suspended in a cold FACS buffer
(PBS containing 1% FCS). Propidium iodide was added to
exclude dead cells. Nanoparticles’ capture was evaluated
as mean florescence intensity (MFI) intensities of the gated
populations, using a BD FACSCanto II flow cytometer and
FACSDiva software (Becton Dickinson).
2.7 MTS cytotoxicity assay
Monocytes (1 x 106 cells/ml) were plated into a 96-well
culture plate the day before the experiment. Cells were then
incubated for 18h with Ludox TM40 NPs at different
concentrations (up to 200 µg/ml) in a complete medium and
with bacterial stimuli. Cellular mitochondrial activity (an
indicator of cellular viability) was evaluated by MTS assay
(Promega), according to the instruction manual.
2.8 Chemotaxis assay
Monocytes or PMNs were purified and immediately
seeded in the upper chamber of a Transwell plate (Corning)
in a complete medium (0.1x106 per condition). The lower
chambers were filled with complete medium only, or with
complete medium containing the different bacterial stimuli
at two concentrations (1 nM and 1 µM), either in presence
or absence of 100 µg/ml of SiO2-NPs. After 2h at 37 °C, the
number of monocytes or PMNs that had migrated into the
lower chamber was estimated by BD FACSCanto II flow
cytometer.
2.9 Superoxide anion production
The cell release of O2.- was estimated by cytochrome c
reduction assay. Briefly, PMNs were incubated at 37°C in
the presence or absence of 100 µg/ml NPs and different
concentrations of bacterial stimuli in HBSS pH 7.4 contain‐
ing 80 µM ferricytochrome c type III (Sigma). Cytochrome
C reduction was evaluated at 550 nm at different time
points using an automated microplate reader (Multiscan
Go, Thermo Scientific).
3. Results
FPR1 and FPR2 activation upregulates the efficacy of
SiO2-NPs to induce cytokines/chemokines release by
monocytes and PMNs. We first characterized the effect of
f-MLP on the intensity of cytokine and chemokine produc‐
tion by monocytes at a concentration (1 nM) only occupying
FPR1, and by PMNs treated with SiO2-NPs. Although f-
MLP was inactive per se, it further increased the intrinsic
efficacy of SiO2-NPs to induce cytokines and chemokines
in both monocytes and PMNs, above the NPs’ dose
threshold of 25 µg/ml [6] (Fig. 1A). RT-PCR analysis (Fig.
1B) indicated that f-MLP increased the synthesis of IL1β,
IL-6 and IL-8 induced by SiO2-NPs (50 µg/ml) in mono‐
cytes, but not that of TNFα, by synergizing the transcrip‐
tion of the mRNA encoded by preIL-1β, IL-6 and IL-8 genes.
Since the transcription rate of these genes are under the
control of NF-kB, the data strongly suggest that f-MLP and
SiO2-NPs synergic action is mediated by this transcription
factor. Consistently, western blot analysis with specific
antibodies indicated an increased expression of NF-kB in
monocytes after 3.5h co-stimulation with both FPR1- and
FPR2- specific agonists and SiO2-NPs, compared to the
expression observed in control cells or in cells treated with
the peptide or nanoparticles only (data not shown).
Having observed the ability of the FPR1 agonist f-MLP to
modulate SiO2-NPs activity, we tested and compared the
action of other peptides binding to the different FPR
isoforms. Dose-response analysis (Fig. 2A) of the effect of
f-MLP on IL-1β released by monocytes stimulated with
SiO2-NPs also confirmed the binding to FPR1 receptors on
these cells to be responsible for the observed synergy. In
fact, cytokine production reached a maximum at peptide
doses (1-3 nM) corresponding to the binding affinity (Kd)
of f-MLP to this receptor. Contrarily, similar to what was
observed in the case of ORMOSIL-NPs [10], this synergy
almost dropped to zero at f-MLP concentrations (~ 1 µM),
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saturating FPR1 and partially titrating FPR2. This biphasic
curve may suggest that the occupation of FPR2 receptors
by f-MLP determines an inhibitory signal, contrasting that
generated by FPR1. Alternatively, high doses of f-MLP may
rapidly induce the downregulation of FPR1. Experiments
performed with the peptides MMK1 and WKYMVM
unable to bind to FPR1, but associating with high affinities
to FPR2 showed that activation of this receptor isoform also
synergized the production of IL-1β by monocytes treated
with SiO2-NPs. Moreover, also in this case, the peptide
effect reached a maximum in correspondence with the
FPR2 Kd (2 nM) and decreased at higher concentrations
(>10-100 nM). In the case of MMK-1 co-stimulation, this
decrease of cytokine synthesis could not be ascribed to the
binding to other low affinity receptors. In fact, the affinities
of MMK-1 for FPR3 and FPR1 was extremely low (Kd=10
mM) or undetectable, respectively. The ability of activated
FPR2 to mediate an increased production of IL-1β was
confirmed by the agonist WKYMVm. This peptide,
characterized by the presence of a D methionine at the C
terminal, is known to bind with a very high affinity to the
FPR2 (Kd=75 pM) and with relatively minor affinities to
FPR3 (Kd=3 nM) and FPR1 (Kd=25 nM). Consistently, the
WKYMVm effect was detected at concentrations ensuring
significant and specific occupation of FPR2 (10-100 pM).
Hence, data collectively indicate that both FPR1 and FPR2
isoforms synergize with SiO2-NPs to induce a strong
secretion of IL-1β by monocytes. However, quantitative
comparisons of data obtained using cells from several
independent donors (N=10) indicate that the FPR1-
mediated effect is three times stronger than the FPR2-
mediated effect (Fig. 2B). Eventually, the co-incubation of
cells with both fMLP and MMK1 determined a cytokine
secretion not dissimilar to those induced by single agonists
in the presence of SiO2-NPs, suggesting no reciprocal
interference between FPR1- and FPR2-mediated signals.
The ability of FPR3 to mediate similar synergic phenomena
in the presence of SiO2-NPs could not be established due to
a lack of specific ligands.
FPRs activations did not increase SiO2-NPs cellular
capture and cytocidal effects. A possible mechanism that
can simply explain the synergy of the FPR agonist to boost
SiO2-NPs’ ability to induce IL-1β may be the induction of a
higher ability to capture nanoparticles and/or to a stronger
sensitivity of cells to the cytotoxic action of SiO2-NPs.
Indeed, f-MLP may induce the overexpression of scavenger
receptors mediating silica NPs’ binding, thereby improv‐
ing the nanoparticle load and their cytotoxic effect. More‐
over, cytotoxicity is well-known to be strictly linked to the
secretion of cytokines [6].
However, the association of FITC labelled SiO2-NPs to
monocytes and to PMNS (not shown) was not significantly
modulated by any of the used peptides, and, consistently,
cell death extent induced by SiO2-NPs was not improved
by FPR1/FPR2 agonists in the full dose range used
(0.01-1000 nM) (Fig. 3).
Figure 1. The effect of f-MLP on the production of proinflammatory cytokines and chemokines induced by SiO2-NPs in monocytes and PMNs. A) Dose
response of IL-1β, IL-6 (monocytes) and IL-8 (monocytes and PMNs) induction by SiO2-NPs in the absence and in the presence of 1 nM f-MLP. Data are the
mean ± SE (N=3); B) Representative RT-PCR analysis, out of three, of the kinetics of the transcription of preIL-1β, IL-6, IL-8 and TNFα genes in monocytes
treated with f-MLP or NPs only, or in combination, as indicated; h indicates the incubation time expressed in hours. mRNA production is expressed as multiples
of the value measured in cells treated with f-MLP only after 1 hour.
5Regina Tavano, Daniela Segat, Chiara Fedeli, Giulia Malachin, Elisa Lubian, Fabrizio Mancin and Emanuele Papini:
Formyl-peptide Receptor Agonists and Amorphous SiO2-NPs Synergistically and Selectively Increase the Inflammatory Responses of
Human Monocytes and PMNs
FPRs activations did not synergize with SiO2-NPs in the
upregulation of antigen-presentation-related proteins in
monocytes. The selectivity of FPR1 and FPR2 agonists in
increasing the production of proinflammatory cytokines/
chemokines was confirmed in other experiments where we
analysed the expression of CD80, CD83, CD86, MHCII and
ICAM-1 (Fig. 4). These membrane proteins are involved in
antigen presentation and T-lymphocytes’ co-stimulation
and their overexpression indicated the induction of the
immunological competence of these cells. Interestingly,
SiO2-NPs determined the over expression of some of these
markers (CD80, CD83, CD 86) but not that of others (MHC-
II and ICAM-1). However, in no cases did f-MLP and
MMK-1, alone or in combination, synergize a statistically
significant over-expression of the level of CD80, CD83,
CD86 and ICAM-1 induced by SiO2-NPs. MHC II expres‐
sion appeared to be increased by SiO2-NPs co-incubated
with peptides, but this trend was not statistically signifi‐
cant. Overall, data indicated that FPR1 and FPR2 activation,
alongside an increase in the production of inflammatory
cytokines, do not stimulate the adaptive immunological
functions of monocytes.
SiO2-NPs differentially modulated the chemotactic
migration induced by FPR1- and FPR2-specific peptides
in PMNs and monocytes, but had no effect on the
activation of NADPH oxidase triggered by the same
agonists. In the previous paragraphs, we have shown how
FPR1- and FPR2-selective peptides further increased the
synthesis of cytokines and chemokines induced by SiO2-
NPs in monocytes and PMNs. We then decided to verify
whether, in turn, SiO2-NPs modulated the major pro-
inflammatory effects mediated by FPRs agonists, that is,
chemotaxis and the activation of the NADPH-oxidase
responsible for the production of superoxide anion. In
Figure 2. The effect of f-MLP, MMK-1, WKYMVM and WKYMYm on the production of IL1β by monocytes in the presence of SiO2-NPs. A) Representative
dose-response curves (out of 10) of the effect of the indicated peptides on the cytokine extracellular release after 24 h, measured by ELISA assay, in the presence
of the indicated NPs concentrations. Within each panel, arrows point to the peptide concentrations approximately corresponding to the Kd values character‐
izing interaction with the indicated FPR isoforms (see also Tab. 1). B) IL1β secretion by monocytes incubated with SiO2-NPs at the indicated doses for 24h in
the presence of the indicated peptides (1 nM). Data are the mean ± SE (N=10). * p<0.05 with respect to f-MLP treated cells.
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agreement with previous studies [14,25-30], all used
peptides stimulated the chemotaxis of both PMNs and
monocytes. Interestingly, SiO2-NPs, although inactive
when tested as single agonists, significantly increased the
chemotactic migration of PMNs induced by f-MLP (FPR1)
but did not modify the one triggered by FPR2-specific
agonists (Fig. 5A). Even in this assay, as in the case of
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Figure 3. Effect of FPR agonists on SiO2-NPs monocytes capture and on SiO2-NPs induced cytotoxicity. A) Cells were incubated for 24h with SiO2-NPs alone
or in the presence of peptides, as indicated and washed and subjected to MTS assay. Values are represented as percentages of alive cells in control cells (no
NPs and no peptide). Data are the mean from three independent experiments run in triplicate. Error bars (± SE), omitted for representation clarity, never
exceeded ± 15%. Differences of values in the presence of peptides with respect to values in the absence of peptides were not statistically significant. B) Cells,
incubated for 24h with fluorescein-labelled SiO2 Stöber-NPs and the indicated peptide doses were washed and the fluorescence associated with cells was
measured by FACS and expressed as mean fluorescence intensity (MFI). Values are means ± SE (N=3).
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Figure 4. The effect of FPR agonists on the expression of immunological activation markers in monocytes treated with SiO2-NPs. Monocytes were incubated
for 24h in the presence of NPs and peptides, as indicated. Cells were then scraped, incubated with different antibodies to the medicated CD markers and the
fluorescence associated with cells was measured by FACS. Data are means ± SE (N=4), * p<0.05 with respect to untreated cells.
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with nanoparticles. Once again, this was due not to the
activation of FPR2 by f-MLP occurring at micromolar
doses, but was instead likely the consequence of rapid
receptor downregulation. In fact, cells’ co-stimulation with
SiO2-NPs and a mixture of f-MLP (1 nM) and FPR 2-specific
MMK 1 (1 nM) did not affect the chemotaxis synergistic
effect. Monocytes’ chemotaxis toward FPR1 and FPR 2
agonists was, on the contrary, not affected or even inhibited
by SiO2-NPs (Fig. 5B).
Eventually, we tested the possible effect of SiO2-NPs on the
production of O2.- by the NADPH-oxidase induced by FPR
agonists. Once again, in agreement with reported evidence
[25, 27-30], both FPR1 and FPR2 agonists stimulated rapid
activation of the respiratory burst in PMNs. The FPR2
agonist WKYMVm was the most efficient, having already
been active at the maximal level at subnanomolar dose,
compatible with its high affinity for the FPR2. F-MLP and
WKYMVM followed and MMK-1 was the least effective.
These data confirmed that both FPR 1 and FPR2 were able
to trigger the typical oxygen dependent antimicrobial
repose of PMNs. In monocytes, such activation is signifi‐
cantly reduced (not shown). The co-incubation with SiO2-
NPs, unable to trigger the activation of the NADPH oxidase
per se, does not affect or improve the kinetics and dose
response of the peptide-induced superoxide production in
PMNs (Fig. 6).
4. Discussion
Understanding and avoiding adverse reactions induced by
nanoparticles is a central aspect of nanomedicine and
nanotoxicology. The standard in vitro toxicological
Figure 5. The effect of SiO2-NPs on the chemotactic migration induced by FPRs’ ligands in PMNs and monocytes. PMNs (A) and monocytes (B) were
seeded in the upper chamber of Transwell plates, in RPMI plus 10% FCS at 37°C, while peptides at the indicated doses and NPs (100 µg/ml) were present in
the lower chambers in the same medium. After two hours, the cells that had migrated into the lower chambers were harvested and counted by FACS. (Data
are means ± SE (N=4); § p<0.05 with respect to control cells; * p<0.05 with respect to cells treated with the same concentration of FPR agonist, but in the absence
of silica nanoparticles.
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approach consists of the exposure of appropriate model
cells to purified nanoparticles in a characterized cell culture
medium. However, the biological effects of nanosystems
are possibly modulated by the presence of agonists
generated only in the host tissues and organs. This may be
especially critical in the presence of microbial infections or
in inflammatory conditions characterized by the presence
of factors from both infectious agents and damaged cells.
These molecules can potentially tilt the balance of nano‐
particles’ action toward toxic-pathogenic effects. Indeed,
several microbial derivatives are known to mediate or
synergize the typical signs of cytotoxic effects, such as ROS
overproduction, or may increase the efficacy of other
proinflammatory stimuli. On the other hand, tissue-
derived molecules, released as a result of cell damage, (e.g.,
ATP or mitochondrial peptides) are also considered major
regulators of inflammatory and immune responses, both in
physiological and pathological processes. In this study, we
found manifold evidence that microbial (PAMPs) and
damaged tissue molecular patterns (DAMPs) could, in
principle, critically increase the bio-hazardous nature of
nanosystems. In fact, we documented a synergistic effect
between amorphous SiO2-NPs, known to determine an
inflammatory and cytotoxic effect both in vitro and in vivo
[6,7,9], and specific agonists for FPRs, a receptor family
specialized in monitoring both bacterial-derived and
cytosolic-derived signals. To do this, we exploited the well
characterized peptides f-MLP (specific to the FPR1 human
isoform in the namolar concentration range), MMK-1
(FPR2-specific in the nanomolar range), WKYMVM (FPR2-
and FPR3-selective) and WKYMVm (binding with very
high affinity to FPR2). We analysed the ability of these FPR
agonists to modulate the intrinsic ability of SiO2-NPs to
trigger cell death and cytokine production in immune cells.
In addition, we examined whether chemotaxis and
NADPH-oxidase activation triggered by FPR agonists in
monocytes and PMNs were modulated by SiO2-NPs.
FPR agonists did not increase the cell sensitivity to NPs-
induced acute toxic effects. However, FPR1 and FPR2
activation increased the production of cytokines, and
especially of the master inflammatory signal IL-1β in the
presence of amorphous silica NPs, with significant effects
detectable at peptide concentrations as low as ~ 10 pM. The
chemotactic migration of PMNs toward nanomolar
concentrations of the FPR1 agonist f-MLP, but not toward
FPR2 specific peptides, was synergistically increased by the
presence of NPs. On the contrary, the chemotaxis of
monocytes toward all tested peptides was not increased by
NPs’ co-treatment, but instead inhibited (Fig. 7). This
inhibitory effect of NPs on the chemotaxis of monocytes
induced by peptides may have been due to sequestration
of the peptide by NPs. However, since in PMNs, at least in
the case of f-MLP, NPs increase chemotaxis, this eventual‐
ity will not compromise the final functional stimulation of
cells.
Collectively, our data suggest that the proinflammatory
effects induced by amorphous silica in vivo may become,
in defined circumstances, much stronger than has thus far
been estimated in vitro. In fact, the presence of even small
concentrations of FPRs-specific molecules released by
either pathogenic or commensal bacteria could exacerbate
the proinflammatory effects of amorphous SiO2-NPs and
possibly of other nanoparticles mediated by myeloid cells.
A similar synergistic effect could also be mediated by
necrotic cells following either infective or sterile tissue
damage. In fact, mitochondria-derived formyl peptides,
normally retained in live cells but released by necrotic or
apoptotic dying cells, bind to both FPR1 and FPR2 with
comparable affinities. We can speculate that an initial
Figure 6









































Figure 6. The effect of SiO2-NPs on the respiratory burst induced by FPRs agonists in PMNs. PMNs were seeded onto 96-well plates and stimulated with
SiO2-NPs (100 µg/ml) alone or together with the indicated concentrations of f-MLP, MMK1, WKYMVM and WKYMVm in RPMI, plus 10% FCS at 37°C. After
10 minutes, O2.- release was estimated spectrophotometrically by cytochrome c reduction assay at 550 nm at different time points. The data given shows a
representative graph out of five for each peptide.
9Regina Tavano, Daniela Segat, Chiara Fedeli, Giulia Malachin, Elisa Lubian, Fabrizio Mancin and Emanuele Papini:
Formyl-peptide Receptor Agonists and Amorphous SiO2-NPs Synergistically and Selectively Increase the Inflammatory Responses of
Human Monocytes and PMNs
condition of tissue damage typical of many pathologies,
microbial infections included, may exacerbate the intrinsic
tendency of amorphous silica nanoparticles to trigger
inflammatory responses of blood-circulating immune cells,
e.g., the PMNs and monocytes tested in this paper. This
event will in turn further amplify tissue and organ damage.
The likely human exposure to nanostructured silica
nanomaterials, due to its broad use as a food and drug
additive, renders the scenario discussed here plausible.
This demands the accurate evaluation of amorphous
nanosilica proinflammatory/cytotoxic potential, not only in
the presence of FPR agonists, but also in the presence of
other signals generated by infectious agents, damaged host
cells and possibly by commensal microbial flora.
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